Figure 3.
PDGFR-β level was found to be a significant predictor for EFS when stratified by metastatic status at diagnosis; p=0.0026 (a). PDGFR-β level was found to be a significant predictor for EFS amongst patients with nonmetastatic disease at diagnosis; p=0.0083 (b). PDGFR-β level was found to be a significant predictor for OS amongst patients with metastatic disease at diagnosis; p=0.0425 (c).